Induction chemotherapy to weekly paclitaxel concurrent with curative radiotherapy in stage IV (M0) unresectable head and neck squamous cell carcinoma: a dose escalation study

Journal of Chemotherapy
S PergolizziN Settineri

Abstract

The purpose was to determine the maximum tolerated dose (MTD) of weekly paclitaxel with concurrent, daily irradiation in patients with unresectable head and neck squamous cell carcinoma previously submitted to induction chemotherapy. Patients with stage IV, and unresectable tumor and/or node/s were enrolled. Nine male patients were submitted to a course of paclitaxel 175 mg/m2 day 1 and cisplatin 75 mg/m2 day 2 given every 3 weeks for three courses. Curative radiotherapy (RT) started 3 weeks after the last cycle of chemotherapy with the goal of delivering a total dose of 66-70 Gy. During RT weekly paclitaxel was administered for 6 courses if feasible; paclitaxel was given according to a dose escalation schema in cohorts of three patients. Dose level A, 30 mg/m2; dose level B, 40 mg/m2; dose level C, 50 mg/m2. During weekly paclitaxel the major toxicity was mucositis that required a treatment break in two of three patients in dose level C; mucositis grade 4 required interruption of paclitaxel administration in all these patients. RT can be given in a continuous fashion with weekly paclitaxel after induction chemotherapy. The MTD of weekly paclitaxel was 40 mg/m2.

References

Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A ForastiereS K Williamson
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C JacobsL Schacter
Jun 1, 1993·Cancer·H ChoyD D Von Hoff
Jul 1, 1997·International Journal of Radiation Oncology, Biology, Physics·W HoffmannM Bamberg
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T G WendtA Schalhorn
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S KiesE E Vokes
Sep 24, 1999·Hematology/oncology Clinics of North America·J Bourhis, J P Pignon
Nov 11, 1999·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·A EckardtJ H Karstens
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S GardenL J Peters
Apr 12, 2000·International Journal of Radiation Oncology, Biology, Physics·M SuntharalingamD A Van Echo
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R PosnerC A Garay
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitchell MachtayUNKNOWN Penn Cancer Center Clinical Trials Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.